Melevodopa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Melevodopa
Accession Number
DB13313
Description
Not Available
Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 211.217
Monoisotopic: 211.084457903
Chemical Formula
C10H13NO4
Synonyms
Not Available
External IDs
  • CHF-1301

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmisulprideThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Amisulpride.
AripiprazoleThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Aripiprazole.
AsenapineThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Asenapine.
BrexpiprazoleThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Brexpiprazole.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Melevodopa.
CariprazineThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Cariprazine.
ChlorpromazineThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Chlorpromazine.
ChlorprothixeneThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Chlorprothixene.
ClozapineThe therapeutic efficacy of Melevodopa can be decreased when used in combination with Clozapine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Melevodopa.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More

Categories

ATC Codes
N04BA04 — MelevodopaN04BA05 — Melevodopa and decarboxylase inhibitor
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Tyrosine and derivatives
Alternative Parents
Phenylalanine and derivatives / Alpha amino acid esters / Amphetamines and derivatives / Catechols / Fatty acid esters / Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Methyl esters / Monocarboxylic acids and derivatives
show 5 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alpha-amino acid ester / Amine / Amphetamine or derivatives / Aralkylamine / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxylic acid ester
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
M30686U4X4
CAS number
7101-51-1
InChI Key
XBBDACCLCFWBSI-ZETCQYMHSA-N
InChI
InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1
IUPAC Name
methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
SMILES
COC(=O)[[email protected]@H](N)CC1=CC=C(O)C(O)=C1

References

General References
  1. AIFA Product Information: Sirio (melevodopa/carbidopa) effervescent tablets [Link]
ChemSpider
21968
ChEBI
134880
ChEMBL
CHEMBL1328898
ZINC
ZINC000019861870
Wikipedia
Melevodopa

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral12.5 MG
TabletOral25 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.15 mg/mLALOGPS
logP-0.2ALOGPS
logP0.62ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)6.97ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area92.78 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity53.85 m3·mol-1ChemAxon
Polarizability21.25 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 14:39 / Updated on October 30, 2020 00:15

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates